Bristol-Myers Squibb: Neoplasms trials

The registry lists 106 Neoplasms studies with Bristol-Myers Squibb as lead sponsor. 7 are open to participants now and 28 have results posted.

Phase 1 81Phase 2 30Phase 3 5Phase 4 1No phase 9(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in JapanRecruitingNCT07755826
• A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsRecruitingNCT06997029Phase 1
• A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant TumorsRecruitingNCT06764771Phase 1
• A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate CancerRecruitingNCT06067841Phase 1
• Pan Tumor Rollover StudyRecruitingNCT03899155Phase 2
• Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T CellsRecruitingNCT03435796Phase 2/3
• A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsRecruitingNCT03093116Phase 1/2
• A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid TumorsCompletedNCT05407675Phase 1/2Results posted
• A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid TumorsTerminatedNCT05071183Phase 1/2Results posted
• Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or MutationsTerminatedNCT04161391Phase 1/2Results posted
• A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)CompletedNCT03744676Phase 2Results posted
• A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)CompletedNCT03668119Phase 2Results posted
• A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced MelanomaActive, not recruitingNCT03470922Phase 2/3Results posted
• Study of Nivolumab for Advanced Cancers in IndiaCompletedNCT03444766Phase 4Results posted
• A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced CancersCompletedNCT03400332Phase 1/2Results posted
• A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell MalignanciesCompletedNCT03310619Phase 1/2Results posted
• A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid TumorsTerminatedNCT03251924Phase 1/2Results posted
• A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has SpreadCompletedNCT03158272Phase 1Results posted
• A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) MalignanciesCompletedNCT03130959Phase 2Results posted
• A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid TumorsCompletedNCT02913313Phase 1/2Results posted
• A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid TumorsCompletedNCT02593786Phase 1/2Results posted
• A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological DisordersCompletedNCT02494258Phase 2Results posted
• Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid TumorsTerminatedNCT02472977Phase 1/2Results posted
• Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)CompletedNCT01964430Phase 3Results posted
• Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid TumorsCompletedNCT01962103Phase 1/2Results posted
• Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line SettingCompletedNCT01946477Phase 2Results posted
• A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid TumorsCompletedNCT01928394Phase 1/2Results posted
• Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) MutationCompletedNCT01915498Phase 1/2Results posted
• A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid TumorsCompletedNCT01714739Phase 1/2Results posted
• Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced CancerCompletedNCT01324323Phase 1Results posted
• Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced CancerCompletedNCT01324310Phase 1Results posted
• Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-DependenceCompletedNCT01178281Phase 3Results posted
• A Study of MDX-1106 in Patients With Selected Refractory or Relapsed MalignanciesCompletedNCT00441337Phase 1Results posted
• Study of Dasatinib (BMS-354825) in Patients With Solid TumorsCompletedNCT00339144Phase 1Results posted
• Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast CancerTerminatedNCT00281528Phase 2Results posted
• Treatment Patterns and Characteristics of Patients Prescribed Opdivo QvantigCompletedNCT07636863
• A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at HomeCompletedNCT06163053
• A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid TumorsActive, not recruitingNCT05888831Phase 1/2
• Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)TerminatedNCT05840510Phase 1
• A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid TumorsWithdrawnNCT05828303Phase 1
• A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer PatientsWithdrawnNCT05828277Phase 1
• Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D MutationTerminatedNCT05737706Phase 1
• A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid TumorsWithdrawnNCT05678283Phase 1
• A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid TumorsCompletedNCT05625412Phase 1
• A Post-Authorization, Long-term Study of Ozanimod Real-world SafetyActive, not recruitingNCT05605782
• A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish DatabaseCompletedNCT05421442
• A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) RegisterCompletedNCT05413044
• A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid MalignanciesTerminatedNCT05209295Phase 1
• Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)CompletedNCT05178888Phase 1
• Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C MutationApproved for marketingNCT05162443
• Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid TumorsCompletedNCT05001516Phase 1
• Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)TerminatedNCT04975256Phase 1
• A Study of BMS-986416 With and Without Nivolumab in Select Solid TumorsCompletedNCT04943900Phase 1
• A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLCTerminatedNCT04849273Phase 1
• Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate CancerCompletedNCT04428788Phase 1
• Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)CompletedNCT04330664Phase 1
• Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in METActive, not recruitingNCT03993873Phase 1
• A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients MalignanciesCompletedNCT03834662Phase 1
• Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1Active, not recruitingNCT03785249Phase 1/2
• A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy SubjectsCompletedNCT03346837Phase 1
• A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's LymphomasTerminatedNCT03220347Phase 1
• A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic NeoplasmsCompletedNCT02842229
• ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid TumorsCompletedNCT02551185Phase 1
• HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid TumorsCompletedNCT02536469Phase 1
• Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant TumorsCompletedNCT02534506Phase 1
• Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)CompletedNCT02286219Phase 1
• Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCompletedNCT02223052Phase 1
• Phase 1/1b Study of MGCD516 in Patients With Advanced CancerCompletedNCT02219711Phase 1
• Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological MalignanciesCompletedNCT02164071
• Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting StateCompletedNCT01930006Phase 1
• Phase 1 Study of CC-486 in Japanese Subjects With Hematological NeoplasmsTerminatedNCT01908387Phase 1
• Effect of SAR302503 on ECG Activity in Patients With Solid TumorsCompletedNCT01836705Phase 1
• Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins LymphomaCompletedNCT01775631Phase 1
• Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced TumorCompletedNCT01750580Phase 1
• Drug Interaction Study of SAR302503 in Patients With Solid TumorCompletedNCT01585623Phase 1
• A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid TumorsCompletedNCT01478685Phase 1
• Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.CompletedNCT01353625Phase 1
• A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or LymphomasTerminatedNCT01163071Phase 1
• Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in JapanCompletedNCT01018745Phase 1
• A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002)CompletedNCT00990912Phase 1/2
• A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung CancerTerminatedNCT00975767Phase 1
• A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.CompletedNCT00915083Phase 1
• A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal AdenocarcinomasCompletedNCT00909402Phase 1
• A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic MalignanciesWithdrawnNCT00820768Phase 1
• Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced CancersCompletedNCT00798252Phase 1
• Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid TumorsCompletedNCT00793897Phase 1
• Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating TanespimycinCompletedNCT00779428Phase 2
• Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced MalignanciesCompletedNCT00697632Phase 1
• Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced MalignanciesCompletedNCT00679133Phase 1
• ABI-009 Trial in Patients With Advanced Non-hematologic MalignanciesCompletedNCT00635284Phase 1
• Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced MalignanciesCompletedNCT00629473Phase 1
• Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid TumorsCompletedNCT00605618Phase 1/2
• Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid TumorsCompletedNCT00569036Phase 1
• ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CarcinomaTerminatedNCT00407407Phase 1
• A Study of BMS-582664 in Patients With Advanced or Metastatic Solid TumorsCompletedNCT00390936Phase 1
• A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid MalignanciesTerminatedNCT00351325Phase 1
• A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid TumorsCompletedNCT00329004Phase 1
• A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced MalignanciesTerminatedNCT00207025Phase 1
• MAD Refractory: Solid Tumor QD w/o BreakCompletedNCT00207012Phase 1
• Study of Dasatinib in Patients With Advanced Solid TumorsTerminatedNCT00162214Phase 1